Comment on the Updated AASLD Practice Guidelines for the Diagnosis, Management, and Treatment of Hepatitis C: Treating Active Drug Users

被引：8
|
作者：
Swan, Tracy [1 ]
Curry, Jen [2 ]
机构：
[1] Treatment Act Grp, New York, NY USA
[2] Harm Reduct Coalit, Oakland, CA USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 01期
关键词：
VIRUS-INFECTION; OUTCOMES; THERAPY; MODEL;
D O I：
10.1002/hep.23077
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：323 / 324
页数：2
相关论文
共 50 条
  • [31] Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users
    Coupland, Heidi
    Day, Carolyn
    Levy, Miriam T.
    Maher, Lisa
    HEALTH PROMOTION JOURNAL OF AUSTRALIA, 2009, 20 (03) : 234 - 240
  • [32] Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice
    Hezode, Christophe
    LIVER INTERNATIONAL, 2012, 32 : 32 - 38
  • [33] Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection
    Alvarez-Uria, Gerardo
    Day, Jeremy N.
    Nasir, Anisa J.
    Russell, Susan K.
    Vilar, Francisco Javier
    LIVER INTERNATIONAL, 2009, 29 (07) : 1051 - 1055
  • [34] On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
    Busschots, Dana
    Bielen, Rob
    Koc, Ozgur M.
    Heyens, Leen
    Dercon, Eefje
    Verrando, Rita
    Janssens, Filip
    Van den Bergh, Luc
    Van Lint, Peter
    Bruckers, Liesbeth
    Nevens, Frederik
    Robaeys, Geert
    BMC PUBLIC HEALTH, 2021, 21 (01)
  • [35] Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Grebely, Jason
    Matthews, Gail V.
    Hellard, Margaret
    Shaw, David
    van Beek, Ingrid
    Petoumenos, Kathy
    Alavi, Maryam
    Yeung, Barbara
    Haber, Paul S.
    Lloyd, Andrew R.
    Kaldor, John M.
    Dore, Gregory J.
    JOURNAL OF HEPATOLOGY, 2011, 55 (01) : 76 - 85
  • [36] Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
    Dimova, Rositsa B.
    Zeremski, Marija
    Jacobson, Ira M.
    Hagan, Holly
    Des Jarlais, Don C.
    Talal, Andrew H.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (06) : 806 - 816
  • [37] Hepatitis C treatment and injecting drug users in Perth, Western Australia: Knowledge of personal status and eligibility criteria for treatment
    Carruthers, Susan J.
    Ryan, Chrissy
    JOURNAL OF SUBSTANCE USE, 2012, 17 (01) : 32 - 40
  • [38] Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting
    Prati, Daniele
    Gasbarrini, Antonio
    Mazzotta, Francesco
    Sagnelli, Evangelista
    Carosi, Giampiero
    Abrescia, Nicola
    Alberti, Alfredo
    Ambu, Silvia
    Andreone, Piero
    Andriulli, Angelo
    Angelico, Mario
    Antonucci, Giorgio
    Ascione, Antonio
    Belli, Luca Saverio
    Bruno, Raffaele
    Bruno, Savino
    Burra, Pitrizia
    Camma, Calogero
    Caporaso, Nicola
    Cariti, Giuseppe
    Cillo, Umberto
    Coppola, Nicola
    Craxi, Antonio
    De Luca, Andrea
    De Martin, Eleonora
    Di Marco, Vito
    Fagiuoli, Stefano
    Ferrari, Carlo
    Gaeta, Giovanni Battista
    Galli, Massimo
    Grieco, Antonio
    Grossi, Paolo
    Licata, Anna
    Maida, Ivana
    Mangia, Alessandra
    Marino, Nicoletta
    Maserati, Renato
    Missale, Gabriele
    Mondelli, Mario
    Nasta, Paola
    Niro, Grazia
    Persico, Marcello
    Petrelli, Enzo
    Picciotto, Antonio
    Piscaglia, Fabio
    Pollicino, Teresa
    Prati, Daniele
    Puoti, Claudio
    Puoti, Massimo
    Raimondo, Giovanni
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (02) : 81 - 91
  • [39] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Haanen, J. B. A. G.
    Carbonnel, F.
    Robert, C.
    Kerr, K. M.
    Peters, S.
    Larkin, J.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2017, 28 : 119 - 142
  • [40] Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
    Philip, Bruggmann
    Sarah, Blach
    Pierre, Deltenre
    Jan, Fehr
    Roger, Kouyos D.
    Daniel, Lavanchy
    Beat, Muellhaupt
    Andri, Rauch
    Homie, Razavi
    Patrick, Schmid
    David, Semela
    Marcel, Stoeckle
    Franco, Negro
    SWISS MEDICAL WEEKLY, 2017, 147
12345